BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T094804
CREATED:20231207T115623Z
LAST-MODIFIED:20231207T115623Z
UID:38307-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:2nd Targeted Intracellular Delivery Summit
DESCRIPTION:Step into the 2nd Targeted Intracellular Delivery Summit\, a thrilling exploration of cutting-edge advancements in drug delivery. This year\, we redefine possibilities\, venturing beyond traditional boundaries with a focus on cellular biology and intracellular mechanisms. \nOptimize drug delivery\, overcome endosomal challenges\, and expand therapies beyond the liver with in-depth case studies and a Pre-Conference Workshop Day. Gain insights into targeted cell interventions for cancer and autoimmune diseases\, re-thinking innovative delivery platforms and strategies for cargo delivery into novel targets. \nEngage in transformative discussions and exclusive case studies with industry giants like Sanofi\, Merck & Co\, Sana Biotechnology\, and Capstan Therapeutics. Uniting C-Level Executives\, Researchers\, and Directors\, this event is the only industry-led forum focused on cellular mechanisms to enable targeted intracellular drug delivery. Addressing challenges in compartmentalization and endosomal escape\, it aims to optimize therapeutic efficacy and minimize toxicity. \nJoin us in March 2024 to delve into the forefront of intracellular targeting\, where innovation meets expertise to propel your drug pipelines toward unprecedented success. \nTo know more visit: https://ter.li/p72w9g
URL:http://www.pharmajournalist.com/event/2nd-targeted-intracellular-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T094804
CREATED:20231207T114720Z
LAST-MODIFIED:20231207T114720Z
UID:38297-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:4th Wet AMD & Diabetic Eye Disease Drug Development Summit
DESCRIPTION:The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit is returning to Boston this upcoming March to unite 70+ industry-based retinal vascular experts from the likes of Bayer\, Boehringer Ingelheim\, Genentech\, Novartis and OcuTerra\, at the only industry-dedicated forum to transform the potential of treatment of chronic\, sight-threatening retinal vascular diseases to improve patient outcomes. \n \nNew additions for 2024 include: \n\nFresh perspectives from the new companies speaking at the 2024 meeting including Aviceda Therapeutics\, Bayer\, Boehringer Ingelheim\, OcuTerra\, Novartis\, Genentech\, and Adverum Biotechnologies\n16+ brand-new speakers out of the 18+ speaker faculty consisting of industry experts and academic leaders working on preclinical models\, choroidal neovascularization\, retinal inflammation\, durable drug delivery to the retinal vascular system and more\nRobust new content focusing on industry-specific topics such as new targets\, in vivo and in vitro models\, retinal imaging and clinical biomarkers and new modalities for retinal and choroidal neovascularization\n\nTo know more visit: https://ter.li/cjnu7k
URL:http://www.pharmajournalist.com/event/4th-wet-amd-diabetic-eye-disease-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T094804
CREATED:20231207T113944Z
LAST-MODIFIED:20231207T113944Z
UID:38292-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:4th Operationalize Expanded Access Programs Summit
DESCRIPTION:Following the increasing interest in access to investigational medicines from patients\, the harmonization of guidance and research on the value of expanded access programs witnesses a critical rise. \nBack in Boston as the only industry forum defining global regulations for EAP and your definitive networking opportunity to connect with managed access teams from other leading and new companies that are immersing themselves in this evolving field of opportunity and life-changing support. \nReunite with 120+ industry experts setting up and leading EAPs at the 4th Operationalize Expanded Access Programs Summit and gain practical take aways on how to construct a reliable system\, define a clear exit strategy\, understand updated local and global regulations\, and determine the role of real-world data to optimize the operationalization of your EAP. This is your one-stop shop to capturing industry’s latest case studies in setting up a program globally\, reaching physicians and patients\, collecting real-world data\, and maximizing vendor selection to improve the operationalization of EAP and streamline access to life-changing therapies. \nWhat’s New for 2024? \n\nA deep dive into the country-level challenges and regulators’ requirements along with the best practices for labelling\, shipping\, and reporting to deliver a successful project across the US\, LATAM and Middle East with UCB\, GSK\, Novartis\, Biogen\, Sanofi\, SpringWorks Therapeutics and Day One Biopharmaceuticals\nA delve into the experiences and perspectives of physicians to better understand their pain points and how they become aware of EAPs to strengthen these relationships and move the field forward with the University of Michigan and Riboscience\nAn active discussion into the role of real-world data and the setup of an EAP through value-based organisations to obtain a large community of patients and carry this out with ease with AstraZeneca\n\nDon’t miss out on your opportunity to be amongst physicians\, patients and passionate EAP and clinical supply experts from Novartis\, Daiichi Sankyo\, GSK\, AstraZeneca\, Gilead\, Biogen\, Sanofi\, Eli Lilly\, Regeneron\, and many more to discover novel strategies in overcoming operational hurdles and deliver life-saving treatments to patients more efficiently. \nTo know more visit: https://operationalize-eap.com/
URL:http://www.pharmajournalist.com/event/4th-operationalize-expanded-access-programs-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T094804
CREATED:20231116T104232Z
LAST-MODIFIED:20231116T104232Z
UID:38153-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy Potency Assay Summit
DESCRIPTION:In the dynamic cell therapy landscape\, the challenge of potency assay development looms large\, as exemplified by clinical holds experienced by Mesoblast and Verve Therapeutics in recent years. \nAt the 3rd Cell Therapy Potency Assay Summit\, we bring together over 120 analytical\, quality control\, and regulatory experts including esteemed organizations like BMS\, J&J\, Atara Biotherapeutics\, Fate Therapeutics\, Health Canada. The summit will address these pressing concerns with the goal to collaboratively design more effective potency assays that not only streamline regulatory approval but also reduce hold times significantly. \nJoin us and leave equipped with industry insights that enable you to develop practical and reproducible assays\, providing a deeper understanding of your cell therapy products. \nFind out more here: https://ter.li/e448ls
URL:http://www.pharmajournalist.com/event/3rd-cell-therapy-potency-assay-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T094804
CREATED:20231108T095535Z
LAST-MODIFIED:20231109T143458Z
UID:38106-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:6th CKD Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for CKD Drug Development \nAdvance More Personalized Therapies for Rare & Common Kidney Diseases \nThe 6th CKD Drug Development Summit is the definitive forum for KOLs\, industry experts\, and regulators to bring kidney innovation onto the next generation of drug development\, uniting 200+ biopharma stakeholders\, from scientific research to clinical development and outcomes\, across three days of concentrated discussion. \nFrom uncovering the genetic architecture of specific CKD subgroups and revolutionizing translatable models of renal pathophysiology\, to breaking new ground in CKD trial design and implementing new therapies into the treatment paradigm\, join Novo Nordisk\, Boehringer Ingelheim\, Eli Lilly\, AstraZeneca\, the FDA\, Regeneron\, Novartis and more to collaborate and drive progress of precision medicine and reinvent the landscape of rare and common kidney disease treatments.
URL:http://www.pharmajournalist.com/event/6th-ckd-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260515T094804
CREATED:20240213T100720Z
LAST-MODIFIED:20240213T100720Z
UID:38674-1710720000-1710979199@www.pharmajournalist.com
SUMMARY:9th Innate Killer Summit 2024
DESCRIPTION:“The translational impact and nature of the work that was being presented were outstanding. You get a lot of insights from your peers regarding their experience interacting with the regulatory agencies” – ONK Tx \nThe 9th Innate Killer Summit is designed for experts striving to realize the clinical potential of NK–based therapies from early discovery to later stages in the clinic through 3 dedicated tracks of content: Pre-clinical\, Clinical Translation\, CMC & Process Development. \nSpecifically focussing on advancing NK engager\, bispecific\, cell therapy\, and combination therapy approaches to improve the clinical durability and streamlining manufacturing. Come together with industry experts to brainstorm best approaches to enhance efficacy and persistence as well as reduce the cost of production. \nCollaborating closely with pioneers such as Dan Kaufman\, Evren Alici\, and industry experts from Zelluna Immunotherapy\, Artiva Biotherapeutics\, Affimed\, Sanofi\, Immunity Bio\, Cytovia (to name a few!) to ensure the critical priorities of the field are captured. Join to gain practical takeaways for novel techniques in engineering NK cells while preserving cell fitness\, best practice clinical trial design methods\, benefits of feeder-free cell expansion and many more! \nRanging from a jam-packed pre-conference workshop day with 6 different workshops and a bootcamp ranging from preclinical to CMC and process development. Also up for offer are 10+ plenary talks across the main conference days where experts will guide you through the current cell therapy landscape\, an industry leaders annual briefing\, a range of clinical data presentations\, and an investors panel!
URL:http://www.pharmajournalist.com/event/9th-innate-killer-summit-2024/
LOCATION:San Diego Marriott Del Mar\, 11966 El Camino Real\, San Diego\, CA\, 92130\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260515T094804
CREATED:20231123T125135Z
LAST-MODIFIED:20231123T125201Z
UID:38203-1710720000-1710979199@www.pharmajournalist.com
SUMMARY:7th Antigen-Specific Immune Tolerance Drug Development Summit
DESCRIPTION:Returning for the seventh year\, the 7th Antigen-Specific Immune Tolerance Summit (March 18 – 20\, 2024 | Boston\, MA) will lean into the industry’s key challenges from details of T-cell assays in preclinical and larger clinical studies; to pioneering CAR-Treg\, mRNA-LNP\, biologic\, peptide\, approaches and updates on proof-of-concept and ongoing clinical programs. This is the highest value meeting on the immune tolerance community’s conference calendar. \nThis is your comprehensive guide to define your pipeline and therapeutic development strategy for 2023\, delve into your opportunity to create tolerizing\, curative\, strategies for autoimmunity\, and tap into your tolerance strategy to tackle immunogenicity and transform the biologic landscape. Network with large pharma scouts\, industry super-giants\, and biotech pioneers to build meaningful partnerships and gather insights beyond the literature. \nExpect to be involved in interactive discussions on: \n\nTackle antigen-selection and deepen your understanding of the role of T-cells\, B-cells and T-regs in immune tolerance evaluate strategies and technologies in complex heterogenous disease settings with COUR Pharmaceuticals and Pfizer.\nBuild the biomarker toolbox and engage in discussions around the true markers of ‘tolerance’ for practical tolerance strategies and markers for determinants of efficacy\, patient selection\, and therapeutic durability with Takeda\, University of Pittsburgh\, Imcyse\, and Anokion\nAssess toxicity and durability of tolerance therapeutics using preclinical models to inform the frequency of administration and the persistence or loss of tolerance over time with Toleranzia and University of Helsinki\nEvaluate delivery technologies and novel approaches including CAR-Treg\, mRNA-LNP\, biologics\, and more to propel tolerizing therapies through proof-of-concept to the clinic with Sonoma\, Moderna\, and Integrated Nanotherapeutics\nHarness mechanistic models and autoimmune disease models to highlight efficacious tolerance induction across diseases including Celiac\, Type 1 Diabetes\, Multiple Sclerosis\, Rheumatoid Arthritis\, and more with GRO Bioscience\, RheumaGen\, NexImmune\, and Parvus Therapeutics\n\nJoin 110+ autoimmune and immunologist scientists\, corporate strategists\, and large pharma scouts at this timely and comprehensive summit set to unite the immune tolerance field. From innovative\, start-up biotechs to big pharma super giants\, this is your unique opportunity to discuss advancing efficacious antigen- and drug-specific tolerance approaches to patients in need. \nDownload the full agenda here to see our full speaker faculty\, 3-day agenda and audience breakdown: https://ter.li/7teig8
URL:http://www.pharmajournalist.com/event/7th-antigen-specific-immune-tolerance-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240312
DTEND;VALUE=DATE:20240316
DTSTAMP:20260515T094804
CREATED:20231215T122622Z
LAST-MODIFIED:20231215T124912Z
UID:38363-1710201600-1710547199@www.pharmajournalist.com
SUMMARY:14th World ADC London 2024
DESCRIPTION:We find ourselves at the cutting edge of oncology innovation\, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collaborations. \nAs such the 14th World ADC London 2024 returns this March as a crucial touchpoint for all antibody drug conjugate developers across Europe. \nThis meeting is the place where innovation meets collaboration to drive antibody-drug conjugates forward and transform cancer therapy as we know it. Uniting 600+ industry experts and ADC newcomers\, this is a conversation you can’t afford to miss. \nTake a look at the full agenda here. \nEmbark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation\, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle. \nHere are some of the leading minds sharing translatable lessons to advance your pipeline including: \n\nAstrid Clarke\, Director\, Head of Early-Stage IND to Medicine Research\,Seagen\nColm Reddington\, Director- Global Regulatory\, Chemistry\, Manufacturing & Control\, AstraZeneca\nDaniel Milano\, Senior Director\, Process Development\, ImmunoGen\nDhiraj Gambhire\, Executive Director – Global Clinical Lead\, Enhertu\, Breast & Medical\, Daiichi Sankyo\nEmmett Scmidtt\, Vice President\, Lead External- Collaborations Project Team Global Clinical Development\, Merck & Co\nGerold Meindhart\, Vice President\, Asset & Portfolio Management\, Daiichi Sankyo\nIan Andrews\, Senior Manager\, Strategic External Development\, GlaxoSmithKline\nKurt Pike\, Senior Director\, External Innovation\, Janssen\nLarisa Stone\, Clinical Development Director\, Gilead\nLolke deHaan\, Vice President\, Toxicology\, ADC Therapeutics\nMike Liao\, Global Clinical Pharmacology Lead\, Genentech\nVenkatesh Pilla Reddy\, Senior Director\, Global PKPD & Pharmacometrics\, Eli Lilly\n\nSee the full speaker faculty and session details here. \nWhether you are pioneering ADC discoveries\, accelerating your conjugate through preclinical and clinical development\, or optimising your CMC efforts\, this is your chance to ahead of the curve with the high-quality and invaluable guidance of the supportive ADC community.
URL:http://www.pharmajournalist.com/event/14th-world-adc-london-2024/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240305
DTEND;VALUE=DATE:20240308
DTSTAMP:20260515T094804
CREATED:20231017T095950Z
LAST-MODIFIED:20231017T095950Z
UID:37964-1709596800-1709855999@www.pharmajournalist.com
SUMMARY:DNA Process Development & Manufacturing Summit
DESCRIPTION:With the cell and gene therapy industry surging\, rapid advances in mRNA-based therapies\, and the advent of DNA vaccines\, the demand for quality DNA as a critical starting and therapeutic material has skyrocketed in recent years. \nThe DNA Process Development & Manufacturing Summit is the only industry-dedicated forum to focus on topics such as DNA construct design\, sequencing technology\, and scaling production for preclinical and clinical programs\, helping to expedited IND submissions and approvals. \nDownload the official event guide here: https://ter.li/9hpxb2 \nInnovative biopharma including BioNTech\, Genentech\, AskBio\, Pfizer\, Roche\, Sanofi and more will unite in Boston to build the ultimate roadmap from plasmids through to synthetic and novel DNA innovations\, helping you advance your manufacturing capabilities for high quality therapeutics and vaccines. \nRegister your place here: https://ter.li/8kdoo7
URL:http://www.pharmajournalist.com/event/dna-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240227
DTEND;VALUE=DATE:20240301
DTSTAMP:20260515T094804
CREATED:20240111T102635Z
LAST-MODIFIED:20240111T102635Z
UID:38483-1708992000-1709251199@www.pharmajournalist.com
SUMMARY:6th Bacteriophage Therapy Summit
DESCRIPTION:The Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Actively engage with the likes of Merck\, Pfizer\, SNIPR Biome\, Locus Biosciences\, Phiogen\, AMR Action Fund and 90+ phage experts to demonstrate positive clinical data and patient outcomes. \nTake advantage of this unique opportunity to be a part of the dialogue\, meet phage leaders\, large pharma\, and venture capitalists to gain practical takeaways\, and demonstrate the clinical utility of your bacteriophage to form meaningful partnerships. \nJoin us for 3 days of unmissable content\, and accelerate your bacteriophage research into clinical\, meaningful and commercially viable therapies. \nCheck out the full event guide now: https://ter.li/jig8n0
URL:http://www.pharmajournalist.com/event/6th-bacteriophage-therapy-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240227
DTEND;VALUE=DATE:20240301
DTSTAMP:20260515T094804
CREATED:20231011T093613Z
LAST-MODIFIED:20240119T123110Z
UID:37931-1708992000-1709251199@www.pharmajournalist.com
SUMMARY:7th CAR-TCR Summit Europe
DESCRIPTION:Cell therapy continues to transform the oncology field\, and this year has also seen the translation of cell therapies’ curative potential into the autoimmune space. \nProviding your team with exclusive access to cutting-edge advances across pre-clinical platforms\, clinical advances\, and streamlined manufacturing\, the 7th CAR-TCR Summit Europe is your must-attend forum to stay at the forefront of these innovations.   \n300+ industry experts will brainstorm enhancing target discovery\, optimizing durability of response and identifying biomarkers to support recruitment\, automating production\, and accelerating analytical processes to reduce operational costs and turnaround times.   \nWith a new Biopharma & Investors Evening\, a new C-Level Think Tank\, new speakers and data from Mnemo Therpaeutics\, Cellectis\, Bambino Gesu Hospital and more\, can your team afford to miss out? \nTo know more visit: https://ter.li/6vgioi
URL:http://www.pharmajournalist.com/event/7th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240226
DTEND;VALUE=DATE:20240229
DTSTAMP:20260515T094804
CREATED:20240213T102528Z
LAST-MODIFIED:20240213T102742Z
UID:38686-1708905600-1709164799@www.pharmajournalist.com
SUMMARY:3rd Next-Generation Conjugates Summit
DESCRIPTION:From Bristol Myers Squibb expanding their cardiovascular partnership with Avidity Biosciences’ antibody-oligonucleotide conjugate technology\, to Nurix and Seagen collaborating on a targeted protein degradation conjugate\, there is now a staggering amount of investment and collaboration in the novel conjugates space. \nAs highlighted above\, drug developers are pushing the boundaries of traditional ADCs by designing and developing novel targeting formats and payloads. Whilst the likes of VincerX Pharma\, Dyne Therapeuitcs and Alnylam are now awaiting clinical validation\, and others continue to innovate in conjugate design\, it is an exciting time for the next-generation conjugates field. \n \nCovering case-study led presentations on novel design concepts\, key translational and clinical development challenges\, and addressing challenging CMC roadblocks\, the Next-Generation Conjugates Summit is your only event uniting developers of a wide array of novel formats and payloads\, with conjugate modality types including antibody-oligonucleotide conjugates\, fragment-drug conjugates\, Targeted Radiopharmaceutical Conjugates\, small molecule-drug conjugates\, bispecific-drug conjugates and more! \nThis is the only event to unite 100+ drug developers from companies of different modality types that would not normally come together\, so make sure to join likeminded conjugate developers to learn\, collaborate and innovate and expand on the potential of conjugate drugs. \nLearn more here: https://ter.li/q5wf9x
URL:http://www.pharmajournalist.com/event/3rd-next-generation-conjugates-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240223
DTSTAMP:20260515T094804
CREATED:20240103T113819Z
LAST-MODIFIED:20240103T113819Z
UID:38417-1708387200-1708646399@www.pharmajournalist.com
SUMMARY:2nd Viral Vector Process Development & Manufacturing
DESCRIPTION:Viral Vector Process Development & Manufacturing Summit\nCreate Qualitative\, Accessible Treatments for Patients \nFollowing Ring Therapeutics’ injection of $86.5m to enhance novel viral vector capabilities\, and BMS’s viral vector facility coming online\, the viral vector market is forecasted to reach $12.8bn – not only in cell and gene therapies but also viral-vector-based vaccines and immunotherapies. \n \nWith the FDA’s fast-evolving quality assessment and lack of standard guidance\, and the continued challenge of viral vector recovery yield and purity\, the 2nd Viral Vector Process Development & Manufacturing Summit is your must-attend meeting in 2024 to help answer your burning questions to enhance process intensification capabilities while meeting regulatory agencies’ expectations. \nIn collaboration with Sarepta\, Ultragenyx\, Affinia Therapeutics\, and UCB\, we will unite 130+ pioneering viral vector up- and downstream process engineers\, MSAT\, CMC to tackle these challenges together. This is your definitive community to seek help from industry pioneers to expedite scale-up\, tech transfer\, and speed-to-clinic. Returning to Boston in February\, we are proud to expand the program into 2 tracks of content as the only industry-led\, end-to-end summit to align with your needs: \n\nDownstream process intensification\, including purification\, to improve recovery and yield\nPurity assessment to uphold GMP and product quality assessment\nDeep dive into upstream process development and cell line in relation to your viral vectors\, and assess platforming strategy\nRapid scale-up with robust analytical capabilities and improve your full:empty capsid ratio and reduce COGs\nMeet and evaluate solution providers and viral vector CDMOs\, including Lonza\, Chromatan\, Teknova\, and Genezen\, to forge long-term relationships\, ensuring tech transfer readiness\n\nIt’s worth clearing 3 days out of your office and joining this summit to leverage novel platform technologies such as continuous processing to improve viral vector manufacturing! \nTo know more visit: https://ter.li/fvlk3e
URL:http://www.pharmajournalist.com/event/2nd-viral-vector-process-development-manufacturing/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240223
DTSTAMP:20260515T094804
CREATED:20231120T110619Z
LAST-MODIFIED:20231120T110619Z
UID:38173-1708387200-1708646399@www.pharmajournalist.com
SUMMARY:6th Annual CRISPR AgBio Congress
DESCRIPTION:The 6th Annual CRISPR AgBio Congress is back on February 20-22\, 2024 (Raleigh\, NC). The dedicated congress that unites industry stakeholders across Agbiotech\, big seed\, distributors\, and investors\, to assess this new regulatory terrain\, examine recent scientific breakthroughs\, and strategize the journey of CRISPR products from editing to delivery\, field to shelf. \nDiscover the full program here. \nBack for its 6th edition\, join the likes of the Pairwise CEO\, and advisors at USDA and EPA as we: \n\nDiscover the latest on the global and US regulatory landscape\, uncover what’s new for standardizing approval processes\, and tackle regulatory compliance for your products\nUncover novel gene editing tools and CRISPR technologies\, AI\, Cas-12\, and CRISPR-enabled breeding and trait discovery tools to address unmet agricultural challenges\nExplore CRISPR product commercialization and effective market targeting strategies for rapid adoption\nTransform agriculture with sustainable crop solutions: explore alternative fuels and precision breeding for enhanced crop sustainability\nUnpick how to enhance the adaptability\, productivity\, and nutrition of orphan and non-model crops such as potatoes\, and strawberries to accelerate breeding and cut costs\n\nView your copy here to find the jam-packed agenda\, with exclusive case studies led by industry giants and regulatory bodies to help you commercialize regulatory-approved gene-edited agriculture products. \nJoin 80+ C-level leaders\, researcher heads\, Molecular Biologists\, Regulatory Experts\, and Product Developers from major seed companies\, innovative Agbiotechs\, influential academic institutions\, and regulatory bodies and be part of the conversation in 2024. \nHere’s what past attendees had to say: \n“Great quality of presentations and coherent style of participants: scientists with key roles in their company and key relevant academic researchers” – Chief Executive Officer\, Meiogenx   \n“The arrangements for the conference\, quality of speakers\, and novel ways to encourage networking were great” – Senior Director\, Yield10 Bioscience
URL:http://www.pharmajournalist.com/event/6th-annual-crispr-agbio-congress/
LOCATION:Sheraton Raleigh Hotel\, 421 South Salisbury St\, Raleigh\, NC\, 27601\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.con
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240213
DTEND;VALUE=DATE:20240216
DTSTAMP:20260515T094804
CREATED:20231123T125801Z
LAST-MODIFIED:20240117T112321Z
UID:38209-1707782400-1708041599@www.pharmajournalist.com
SUMMARY:3rd mRNA Analytical Development Summit
DESCRIPTION:100+ Technical mRNA Specialists | 35+ Expert Speakers \nAs access to faster and higher-throughput analytical methods becomes increasingly vital\, it is critical that we employ superior analytical approaches for mRNA-based therapeutics and vaccines to ensure high quality and effective drugs are approved\, whilst adhering to regulatory guidelines. \nThe 3rd mRNA Analytical Development Summit returns to Boston in February to seek and discuss new guidelines and identify a path forward with tangible best practices to ensure reliable analytical methods are guiding mRNA production\, purification and formulation optimization for approval of high quality\, compliant mRNA drugs for patients in need. \nDownload the three day program here: https://ter.li/pi54tj \n100+ Heads\, Directors and Senior Scientists of Analytical Development\, Quality Control\, CMC and Regulatory Affairs will deep dive into analytical development techniques and challenges within mRNA drug product and drug substance\, eager to glean insights into future analytical methods to safeguard regulatory submissions in 2024 and beyond. \nJoin them and register your place here: https://ter.li/d6nqe3
URL:http://www.pharmajournalist.com/event/3rd-mrna-analytical-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240213
DTEND;VALUE=DATE:20240216
DTSTAMP:20260515T094804
CREATED:20231101T110512Z
LAST-MODIFIED:20231101T111904Z
UID:38062-1707782400-1708041599@www.pharmajournalist.com
SUMMARY:4th Gene Therapy Comparability Summit
DESCRIPTION:As we witness a surge in later-stage clinical trials within the gene therapy industry\, the spotlight on comparability has never been brighter. That’s why we’re thrilled to announce the return of the 4th Gene Therapy Comparability Summit\, taking place in Boston\, MA\, February 13-15. \n \nThis event is your gateway to uncovering how to implement effective comparability studies to overcome strategic and technical hurdles to expedite more gene therapy approvals. \nWhat to expect at the 2024 meeting: \n\nGain valuable insights from CSL Behring\, Bayer\, Ultragenyx\, and other industry leaders on the transition to in-house manufacturing\, effective variability management\, and ensuring consistency across multiple facilities.\nExamine Sarepta’s considerations before and after receiving regulatory approval and investigate the distinctions among global regulatory agencies with insights from Novartis\, Sarepta\, and Adverum.\nStrengthen your analytical toolbox and enhance comparability studies through case studies and strategies to reduce variability with AskBio and BioMarin.\nStay ahead of the latest advancements in process development for improved characterization and analysis of AAV-gene therapies\, with a focus on minimizing process alterations\, featuring contributions from Abbvie and Spark Therapeutics.\nHarness strategic insights from cell therapy study design\, innovative analytical techniques\, and regulatory expertise to enhance your gene therapy comparability protocols\, supported by Novartis.\n\nDon’t miss this unparalleled opportunity to stay at the forefront of gene therapy comparability. Join us and gain the knowledge\, tools\, and connections to secure your gene therapy approval. \nDownload the full event guide here to view the full expert speaker line up and see who else you will meet: https://ter.li/rrefvp
URL:http://www.pharmajournalist.com/event/4th-gene-therapy-comparability-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240130
DTEND;VALUE=DATE:20240202
DTSTAMP:20260515T094804
CREATED:20240105T091432Z
LAST-MODIFIED:20240105T091432Z
UID:38450-1706572800-1706831999@www.pharmajournalist.com
SUMMARY:8th Microbiome Movement - Drug Development Summit Europe
DESCRIPTION:As Europe’s premiere microbiome conference tightly focused on the development of microbiome-based therapeutics\, this is your prime opportunity to expand your microbiome-based drug development capabilities and business potential as we aim to deliver clinical results and ensure therapeutic microbiome approval in Europe. \nNo matter what stage of development you’re focusing on\, this is your one-stop shop for microbiome-based drug development from early discovery to late-phase manufacturing! \nWhat’s New for 2024: \n\nHighlighting early-stage organisations and their novel technologies in our brand-new technology showcase where we welcome Centre for Genomic Regulation\, Recolony and Synflora to give quick fire presentations to showcase their work.\nDiscover our new enabling technologies track to learn more about the exciting artificial intelligence\, integrated -omics analysis and improved manufacturing capabilities among the other technologies that are accelerating microbiome-based drug development.\nStrengthen your regulatory understanding and enhance decision-making by uncovering global regulations to address updated SoHo frameworks\, explore considerations for engineered microbes and consolidate agencies interactions\n\nTo know more visit: https://ter.li/zi3xwf
URL:http://www.pharmajournalist.com/event/8th-microbiome-movement-drug-development-summit-europe/
LOCATION:Hotel Barceló Sants\, Pl. dels Països Catalans\, s/n\, 08014\, Barcelona\, 08014\, Spain
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240130
DTEND;VALUE=DATE:20240202
DTSTAMP:20260515T094804
CREATED:20231206T112751Z
LAST-MODIFIED:20231206T112751Z
UID:38270-1706572800-1706831999@www.pharmajournalist.com
SUMMARY:2nd Next Generation Ophthalmic Drug Delivery Summit
DESCRIPTION:The 2nd Annual Next Generation Ophthalmic Drug Delivery Summit is returning to San Francisco this January to unite 90+ device engineers\, biochemists\, preclinical and clinical experts as they discuss how they are optimizing longer-lasting and less invasive delivery to the back of the eye to reduce patient concerns and burden on healthcare systems caused by frequent drug administration. \nJoin 23+ expert speakers from the likes of AbbVie\, Boehringer Ingelheim\, Bayer\, Genentech\, Janssen\, Novartis\, and Clearside Biomedical at the only industry-dedicated event focusing on overcoming key translational challenges of developing and implementing novel delivery technology as they progress their ophthalmic pipelines to the clinic. \nTo know more visit: https://ter.li/o3pq3n
URL:http://www.pharmajournalist.com/event/2nd-next-generation-ophthalmic-drug-delivery-summit/
LOCATION:The Marker San Francisco\, 501 Geary St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240123
DTEND;VALUE=DATE:20240126
DTSTAMP:20260515T094804
CREATED:20231006T112619Z
LAST-MODIFIED:20231006T112619Z
UID:37924-1705968000-1706227199@www.pharmajournalist.com
SUMMARY:3rd mRNA-Based Therapeutics Summit Europe
DESCRIPTION:250+ mRNA Specialists | 40+ World-Class Speakers | 2 Streams of Content \nThe 3rd mRNA-Based Therapeutics Summit Europe returns to Berlin this 23rd-25th January to unite European biopharma\, to hear from the likes of BioNTech\, CureVac\, Moderna\, Pfizer\, Ethris\, Sanofi\, and regulatory insights for the MHRA and EMA. \nDownload the full brochure here: https://ter.li/1329up \nThis is your opportunity to hear the hottest content of the mRNA world\, deep diving into two content tracks on Translational Development and CMC\, a pre-conference Focus Day on AI RNA Design & Delivery\, and three immersive pre-conference workshops. \nJoin in January to understand the roadmap towards clinical success and regulatory approval\, and deliver the promise of better mRNA medicines to patients faster. \nBook your place here: https://ter.li/qu2h8f
URL:http://www.pharmajournalist.com/event/3rd-mrna-based-therapeutics-summit-europe/
LOCATION:Mecure Hotel MOA Berin\, Stephanstraße 41\, Berlin\, 10559\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240123
DTEND;VALUE=DATE:20240126
DTSTAMP:20260515T094804
CREATED:20230927T095451Z
LAST-MODIFIED:20230929T103625Z
UID:37864-1705968000-1706227199@www.pharmajournalist.com
SUMMARY:Gene Therapy Regulatory Affairs Summit
DESCRIPTION:With 2023 welcoming newly FDA-approved gene therapies from BioMarin\, Krystal Biotech and Sarepta Therapeutics\, many more treatments are hot on their heels for approval\, investment is pouring into developing gene therapies and the role of regulatory affairs has never been more important. \nAs the first ever regulatory affairs forum wholly dedicated to gene therapy\, this meeting uniquely unites regulatory bodies and the leading regulatory personnel across big pharma and innovative biotech to discuss the hottest topics\, identify industry bottlenecks and offer actionable insights. \nJoin 80+ industry leaders from 4D Molecular Therapeutics\, Advanced Cell & Gene Therapy\, Adverum Biotechnologies\, Astrazeneca\, Bridge Bio\, Health Canada\, Omega Therapeutics\, Opus Genetics\, Regeneron Pharmaceuticals\, Sangamo Therapeutics\, Solid Biosciences\, Spark Therapeutics\, Ultragenyx Pharmaceutical\, and more… \nBy attending this summit\, you will get a chance to: \n\nUnderstand the nuanced differences and the route to harmonization in global regulation across the EMA\, MHRA\, FDA & Health Canada\nHone your regulatory intelligence\, understand how to use biomarkers as surrogate endpoints and perfect clinical trial strategy for regulatory success\nExplore the next steps for specific technologies beyond AAV and novel regulatory route\nHear from the regulators in the Health Canada and the FDA to have your queries clarified\n\nOvercome your CMC hurdles to prove the efficacy\, purity & comparability of your compound to avoid later setbacks in poor manufacturing preparation \nDon’t miss out on this unrivalled opportunity to inform your trial design\, perfect your CMC approach and supercharge your global submission strategy for regulatory success. \nDownload the full agenda here to see our full speaker faculty\, 3-day agenda and audience breakdown: https://ter.li/sgkcr9
URL:http://www.pharmajournalist.com/event/gene-therapy-regulatory-affairs-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240109
DTEND;VALUE=DATE:20240112
DTSTAMP:20260515T094804
CREATED:20231026T085211Z
LAST-MODIFIED:20231026T085354Z
UID:38024-1704758400-1705017599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices Europe
DESCRIPTION:SAE Media Group’s 16th Annual Pre-Filled Syringes and Injectable Drug Devices Conference will return to London in January 2024 to unite leaders from the industry and bring you the latest advances in the combination product drug delivery space. \n \nYear on year\, the field of injectable drug delivery has witnessed remarkable progress\, marked by advancements in device technology\, including smart devices and those designed for large volume drug administration. There has been a shift towards enhancing the patient experience through innovative device design. Moreover\, the industry is now moving towards a circular approach for environmental sustainability\, incorporating it into device manufacturing and design\, as well as device usage. The upcoming conference aims to tackle pressing industry challenges by exploring them through real-world case studies and valuable insights while also considering opportunities for the future. \nAs part of SAE’s leading Injectable Drug Delivery Series\, the 3-day event will comprise of a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference comprising of morning keynote plenaries and parallel afternoon topic streams as detailed below addressing the industry’s hottest topics: \n\nDevice Innovations for Large Volume and Highly Viscous Drug Delivery\nSustainability by Design and Material Selection\nPrimary Packaging Development\nDigital Integration for Connected Devices\n\nThis event will not only bring you key insights needed to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in January 2024! \nBenefits of attending:  \n\nEngage with pharma\, biotech and device developers on the latest trends within the pre-filled syringe and injectable device market\nHear about new technological advances in the delivery of large volume drugs and novel drug products\nUnderstand the latest regulatory requirements from experts surrounding medical devices and digital health\nGain insight into how big pharma is incorporating sustainable approaches into drug device design\nDelve into the growing potential of digital health to improve patient experience and treatment\n\nExplore key considerations for material components for the development of primary packaging \nTo know more visit: www.pre-filled-syringes.com/PharmaJournalist-WL
URL:http://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-europe-2024/
LOCATION:LEONARDO ROYAL HOTEL LONDON TOWER BRIDGE\, 45 Prescot Street\, London\, E1 8GP\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231213
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T094804
CREATED:20230907T095249Z
LAST-MODIFIED:20230907T095249Z
UID:37740-1702425600-1702598399@www.pharmajournalist.com
SUMMARY:Gene Therapy Process Development Summit
DESCRIPTION:The inaugural Gene Therapy Process Development Summit is a must-attend to discover the latest insights to bridge the gap between R&D and process development\, ensuring that high-quality gene therapies are manufactured repeatably\, at scale\, and in a cost-effective manner. \nJoin us in Philadelphia to discover and learn the latest insights through case study presentations\, informative panel discussions\, and deep-dive workshops from Ultragenyx\, REGENXBIO\, Janssen\, Amgen\, Astellas Gene Therapies\, and many more! \nWhether you are looking to improve your platform processes or shorten development timelines this summit will be a unique opportunity to meet and network with peers to discuss successes and challenges in your process development journeys. \nJoin your peers to: \n\nLearn how to achieve the ideal complex size with Meira GTx by using automation and process analytical tools to optimize transient transfection leading to enhanced efficiency\, time saving and scale-up insights\nDeep dive into enhancing the Pinnacle PCL Platform 2000L batch process with Ultragenyx to increase yield\, improve product quality and reduce time-to-clinic\nExamine case study results with Astellas Gene Therapies and explore the optimization techniques to cut costs and streamline tech transfer and scale-up times\nExplore the design principles for creating robust AAV producer cell lines to yield a stable and consistent AAV production to optimize AAV vector generation to improve your platform processes with Lacerta and REGENXBIO\nUnpick the ever-changing\, complex regulations surrounding the world of gene therapy in a detailed workshop that doubles down on development strategies that are adaptable to the challenges by gene therapy to prevent regulatory roadblocks when trying to get drugs to clinic\n\nDownload the full agenda here to see our full speaker faculty\, 2-day agenda and audience breakdown: https://ter.li/nxp0nz
URL:http://www.pharmajournalist.com/event/gene-therapy-process-development-summit/
LOCATION:Le Meridien Philadelphia\, 1421 Arch Street\, Philadelphia\, PA\, 19102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T094804
CREATED:20231031T110228Z
LAST-MODIFIED:20231031T110322Z
UID:38052-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:8th Oncolytic Virotherapy Summit 2023
DESCRIPTION:Following recent struggles in the industry\, the leading annual 8th Oncolytic Virotherapy Summit returns to Boston\, MA in December (12-14)\, as the industry’s definitive\, and most comprehensive forum. Bringing you 29+ world-class speakers\, 10+ hours of networking\, 2-panel discussions\, 1 pre-conference focus day & more. This event will be showcasing brand-new pivotal data to ensure a pathway of success for regulatory approval of OV drugs. \n3 days of carefully curated sessions will gather 100+ OV trailblazers across sessions spanning Early Discovery\, Translation\, Clinical Development\, Chemistry\, Manufacturing & Controls (CMC)\, and Regulations to overcome the industry’s largest and critical bottlenecks. Here is just a snapshot of our world-class speaker line-up who will be showcasing their expertise and critical updates: \n\nRichard Dambra\, Scientist\, Viral Platforms\, Boehringer Ingelheim\nFrancesca Barone\, CSO\, Candel Therapeutics\nMichael Franti\, Director\, Viral Platform Drug Metabolism & Pharmacokinetics\, Boehringer Ingelheim\nPaul Hallenbeck\, Chief Scientific Officer\, Seneca Therapeutics\nTalia Biran\, President Clinical Development Operations\, Oncolys\n\nThis year’s edition brings highly promising content such as the exclusive Innovation Showcase\, a whole day dedicated to Clinical Design & Manufacturing Strategies and a must-attend Investor Panel from experts in Biopharma. \nAs the only and longest established end-to-end OV-focused conference\, this is a crucial date in the industry calendar you cannot afford to miss. \nTo know more visit: https://ter.li/1ag3m6
URL:http://www.pharmajournalist.com/event/8th-oncolytic-virotherapy-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T094804
CREATED:20231018T112219Z
LAST-MODIFIED:20231018T112219Z
UID:37976-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:Health Economics & Outcomes Research Summit
DESCRIPTION:The Health Economics & Outcomes Research Summit is a focused intimate gathering of HEOR professionals\, moving past basic introductions to advanced tactical and strategic conversations best leveraging innovative methods to demonstrate the value proposition of new drugs to secure formulary and market access. \nHear cutting-edge case studies into evidence generation\, modeling and real-world evidence across oncology\, neurology\, cardiovascular\, rare diseases\, and beyond. Explore how leading pharma and pioneering biotechs are navigating this changing landscape including:  \n\nAdapting value assessments for evolving reimbursement requirements\nAdjusting to price control mechanisms implemented by the Inflation Reduction Act\nLeveraging advances AI to revolutionize data-driven decision-making \n\n\nJoin this gathering of HEOR experts and gain strategic and commercial market intelligence by exploring how thought leaders are redefining a robust strategy to demonstrate the clinical effectiveness\, safety\, and cost-effectiveness of new drugs\, don’t miss out on your opportunity to fortify a resilient decision-making framework.  \nTo know more visit: https://bit.ly/3PTp5M4
URL:http://www.pharmajournalist.com/event/health-economics-outcomes-research-summit/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T094804
CREATED:20230914T091348Z
LAST-MODIFIED:20230914T091348Z
UID:37788-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:6th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:200+ Attendees | 33+ World-Class Speakers | 23+ Data Driven Case Studies \nReturning to Boston this December for its 6th year\, the RNA-Targeted Drug Discovery & Development Summit is the only industry-dedicated forum solely focused on small molecules targeting RNA\, with a core focus on improving selectivity and specificity to enable safe and effective drugs into the clinic. \nView the program here: https://ter.li/xq2eye \n2023 has seen advances in artificial intelligence\, screening tools and progression into the clinic\, coupled with numerous strategic collaborations and investments into early discovery. \nBringing together 33+ experts presenting the latest data and case studies straight from the lab\, alongside senior decision makers discussing key breakthroughs and strategy\, this year’s meeting is a must-attend if you are looking to turbocharge discovery and development of small molecules targeting RNA. \nRegister here: https://ter.li/r67ejq
URL:http://www.pharmajournalist.com/event/6th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T094804
CREATED:20230908T111459Z
LAST-MODIFIED:20230908T111459Z
UID:37759-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:Covalent Drug Discovery Summit
DESCRIPTION:Bringing the covalency field under one roof for the first time\, the inaugural Covalent Drug Discovery Summit comes to Boston this December – gathering 80+ covalent drug specialists from the likes of Amgen\, Revolution Medicines\, Novartis\, Totus Medicines\, Covant Therapeutics and more. \nThis is a unique opportunity to network with an audience of CXOs\, VPs\, Directors and Heads of Discovery\, Medicinal and Biological Chemistry focused on covalent drug discovery. \nHear from 20+ industry leaders across three days of carefully curated content\, engage in dedicated networking time with the field\, ask your burning questions to our expert speakers at the end of each presentation\, and dive deep into two interactive workshops on toxicity and safety concerns and the future of covalency. \nDownload your copy of the program here to find out more: https://ter.li/z6hwj6
URL:http://www.pharmajournalist.com/event/covalent-drug-discovery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260515T094804
CREATED:20230920T102331Z
LAST-MODIFIED:20230920T102331Z
UID:37817-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd Applied Biocatalysis Summit
DESCRIPTION:Enzyme Engineering Enabling Scalable Industrial Biotransformation for Sustainable API Production \nIn 2023\, an era of advanced enzyme engineering technology is rapidly enabling the generation of game-changing enzymes for novel transformations. As witnessed for Merck’s Islatravir and BMS’ ERED/KRED biocatalytic cascade recognition\, industries are fast transitioning towards biocatalysis to capitalize on more sustainable means of synthesis. The 3rd Applied Biocatalysis Summit is your must-attend meeting dedicated to accelerating enzyme discovery and reaction route development\, through to scaling process chemistry for industrial applications. \nWith unmissable case studies from the likes of Merck\, Amgen\, Sanofi\, Biogen\, GSK\, and Pfizer\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nGaining valuable insights on chemoenzymatic catalysis research\, combining heterogeneous and homogeneous catalysis and making valued functionality using biocatalysis\, in water with Bruce Lipshutz\, Professor of Chemistry\, University of California\, Santa Barbara\nLearn how new technologies are adding efficiencies to biocatalysis’ adoption\, including AI/ML approaches\, improved screening for reaction prediction & new chemistry discoveries with Merck & Pfizer\nEngage in dynamic panel discussions addressing how cross-departmental collaboration enable the faster assessment and introduction of enzymatic catalysed reactions as early as possible with AbbVie\, Biogen & Neorocrine Biosciences\n\nDon’t miss this opportunity to join trailblazers and accelerate enzyme discovery and engineering\, discover carbon footprint-reducing reactions and refine your process scaling strategies.
URL:http://www.pharmajournalist.com/event/3rd-applied-biocatalysis-summit/
LOCATION:The Study at University City\, 20 S 33rd Street\, Philadelphia\, PA\, 19104\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260515T094804
CREATED:20230915T100043Z
LAST-MODIFIED:20230915T100043Z
UID:37804-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd ADC Target Selection Summit
DESCRIPTION:The 3rd ADC Target Selection Summit (December 5-7 | Boston\, MA). This is the ultimate cover-to-cover conference providing insights to help you optimize the pairing of target\, antibody\, and linker-payload and develop the next generation of clinically successful ADCs beyond HER2 and TROP2. \nSee the full program here. \nAs the number of new clinical ADC targets continues to increase\, this year’s meeting will have a greater focus on identifying and validating novel targets\, re-examining what makes a good target\, and delving into the use of proteomics to ensure you get the first step of drug development right. \nHere are some of the agenda highlights you cannot afford to miss: \n\nJoin Cancer Research Horizons to learn “Overcoming Hurdles in Validating Novel Targets for Clinically Applicable ADCs” and hear how an unbiased proteomics approach with patient samples was used to discover a clinically relevant ADC target for multiple myeloma\nHear from Ziel Bio on “Discovering Cell Surface Plectin: A Highly Promising Target for Multiple Solid Tumors” to understand how the hypothesized function of plectin highlights it as a good ADC target\, and learn how ZB131 can selectively bind to CSP improving internalization and minimizing off-target effects\nGain insights from AstraZeneca on “A Case Study on Utilizing Hindsight Following Progression of an ADC With a HER2 Target Into the Clinic” highlighting the target selection process and reasons behind the choice of pursuing HER2\, target and antibody considerations; and emphasizing challenges and successes in the use of this target for ADCs to help you prepare for your development.\n\nTake a look at the full speaker faculty and session details. \nUniting 100+ of your peers working in biology\, discovery and oncology research\, this unique forum will provide you with an exclusive opportunity to learn and network with other ADC developers who are living and breathing targets all in one room.
URL:http://www.pharmajournalist.com/event/3rd-adc-target-selection-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260515T094804
CREATED:20230829T091427Z
LAST-MODIFIED:20230829T091427Z
UID:37688-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:Advanced Purification for Complex Biologics Summit
DESCRIPTION:The Advanced Purification for Complex Biologics Summit is the first and only standalone conference focused on purification for biologics and novel modalities bringing together purification\, CMC and MSAT professionals to collaborate and remove purification bottlenecks to meet market delivery timelines. \nThis in-depth 3-day event will feature the latest breakthroughs and cutting-edge content in AI and digital learning tools to help you save time during downstream processing and boost efficiency. \nThis is your unique opportunity to meet 60+ purification and downstream processing experts including Sanofi\, Takeda\, Eli Lilly\, AstraZeneca and Regeneron as they talk you through machine learning\, predictive modelling\, and consumables advancements to empower your process optimization\, moving a step closer to 100% product purity. \nTo know more visit: https://ter.li/80pxjz
URL:http://www.pharmajournalist.com/event/advanced-purification-for-complex-biologics-summit/
LOCATION:Sonesta Philadelphia Rittenhouse Square\, 1800 Market Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260515T094804
CREATED:20230825T133450Z
LAST-MODIFIED:20230825T133450Z
UID:37674-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:4th Annual CRISPR 2.0 Congress 2023
DESCRIPTION:CRISPR represents the next frontier in the cell and gene therapy landscape. Spearheaded by the first gene edited therapeutic awaiting FDA approval\, a mounting wave of innovative technology developments and therapeutic applications are leading to a paradigm shift in our global healthcare systems. \nTo this end\, the 4th Annual CRISPR 2.0 Congress is your definitive guide to showcasing the latest and greatest CRISPR tools being developed and applied in the therapeutic setting. \nTo know more visit: https://ter.li/rqwuyn
URL:http://www.pharmajournalist.com/event/4th-annual-crispr-2-0-congress-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR